Flow Imaging Microscopy Bridges the Gap in Subvisible Particle Testing for Biologics, USP Stimuli Article Says

Subvisible particles (SbVPs) have become one of the most rigorously examined quality attributes in sterile drug manufacturing, and conventional optical methods are struggling to keep pace with the complexity of modern biologics. A recent US Pharmacopeia (USP) "Stimuli to the Revision Process" article highlights the importance of orthogonal approaches such as Flow Imaging Microscopy (FIM) to distinguish silicone oil droplets (SiOPs) from protein aggregates (搜索)搜索该靶点, according to a new application note from Yokogawa Fluid Imaging Technologies (搜索)搜索该词条.

Why Light Obscuration Falls Short

Light obscuration (LO) remains the most widely used method for measuring subvisible particulate matter in parenteral medicinal formulations. It works by detecting how much light particles block as they pass through a laser, then sizing each particle based on the shadow it casts. However, LO is ineffective at detecting low-contrast particles such as protein aggregates (搜索)搜索该靶点 and silicone oil droplets because of their low refractive index.

Proteinaceous SbVPs are particularly difficult to characterize with conventional optical methods, a limitation that constrains the ability to assure compliance with critical quality attribute (CQA) requirements outlined in compendial procedures and published in recognized pharmacopeias. Because subvisible particles are undetectable to the human eye yet sufficiently large to pose immunogenicity risks, particularly in biological drug formulations, this analytical gap carries direct implications for product stability, quality, bioavailability and patient safety.

FIM collects high-resolution images for direct measurement, enabling thorough morphological characterization and precise particle-type distinction — capabilities that LO alone cannot provide.

Regulatory Framework and the Prefilled Syringe Challenge

The USP Stimuli article discusses the challenges in characterizing SbVPs across protein therapies (USP <787>), parenteral medication products (USP <788>), and therapeutic injections and ophthalmic solutions (USP <1788>). Within this framework, compendial chapters numbered below 1000 establish mandatory limits, while informational chapters numbered 1000 and higher provide guidance on best practices and are not independently enforceable. Regulators increasingly cite the informational chapters in audit discussions and warning letters, lending them significant practical importance.

The analytical challenge has intensified as prefilled syringes (PFS) lubricated with silicone oil have emerged as the preferred primary container for biologics. Determining whether and how SiOPs interact with therapeutic proteins — potentially influencing stability, aggregation behavior and overall product quality — cannot be met solely by LO. Light obscuration alone cannot differentiate between protein aggregates (搜索)搜索该靶点, silicone oil droplets originating from prefilled syringes, and rubber particles resulting from stopper interactions, a primary regulatory challenge that USP <1788> aims to address.

Study Design: Two Arms, One Analytical Question

The findings are presented in two separate study arms. In the first arm, FlowCam (搜索)搜索该药品, a FIM instrument, demonstrates how morphological data can be used to count, measure and categorize flick-generated SiOPs separately from freeze-thaw (FT)-stressed human IgG查看药品详情 (hIgG) aggregates, which are studied individually and in defined ratio metric blends.

Silicone-oil-lubricated PFS present a unique challenge: FT stress can cause both protein aggregation and SiOP shedding, resulting in mixed low-refractive-index particle populations that compendial LO consistently underestimates.

The second arm of the investigation addresses this challenge by assessing the FT stability of hIgG in silicone-oil-lubricated PFS using FlowCam (搜索)搜索该药品 LO, which allows for simultaneous FIM and LO measurements. Because PFS act as both storage containers and delivery devices, International Council for Harmonization (ICH) guideline Q5C and combination product stability expectations require FT stress testing in the anticipated final container-closure system, not just the bulk solution.

From Detection to Root Cause

By incorporating FlowCam (搜索)搜索该药品 into the analytical workflow, manufacturers receive the comprehensive insights needed to identify the core causes of particle generation and develop effective mitigation methods when drug products exceed compendial limitations. The study shows how FIM enhances traditional LO workflows by providing the visual and quantitative evidence required to bridge these gaps.

The broader guidance in USP <1788> reinforces several principles central to this approach: orthogonal methods are expected because no single technology fully characterizes all particle types; sample handling factors such as mixing, temperature, container type and environmental controls can substantially alter results; method-dependent differences in particle counts are normal and should be explained during method validation rather than treated as discrepancies; and particle identity — whether protein aggregates (搜索)搜索该靶点, silicone oil droplets, foreign matter or inherent excipient particles — is essential for making appropriate quality decisions.

The same rationale extends to ophthalmic products, where USP <789> imposes more stringent limits than <788> due to the sensitivity of ocular tissues. Intravitreal injections, including anti-VEGF therapies and gene therapy vectors, fall under the purview of <789> and present similar challenges for protein aggregate characterization as parenteral biologics.

FlowCam (搜索)搜索该药品 instruments, which combine digital imaging, flow cytometry and microscopy into a single solution, have been deployed in over 50 countries supporting research, development and environmental monitoring in the life sciences, materials research and industrial applications.